News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Glenmark Pharmaceuticals Signs Asthma Drug Deal With Japanese Firm; $53 Million


10/19/2005 5:10:53 PM

BOMBAY, April 26 (Reuters) - India's Glenmark Pharmaceuticals Ltd. (GLEN.BO: Quote, Profile, Research) said on Tuesday it had licensed an asthma treatment molecule to Teijin Pharma Ltd. for development and marketing in Japan, in a deal worth up to $53 million. This follows a tie-up with U.S. rival Forest Labs Inc. (FRX.N: Quote, Profile, Research) for development and marketing of the drug, which aims to treat chronic obstructive pulmonary disorder (COPD), in North America. The deal with Forest, worth up to $190 million, is the largest licensing agreement struck by any Indian drug maker.

Read at Reuters
Read at India Infoline
Read at PharmaBiz

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES